• Aurinia Pharmaceuticals initiated PRESERVE, a Phase 4 study testing LUPKYNIS in combination with select biologics in lupus nephritis.
• Trial targets about 150 patients across about 50 US sites.
• Primary endpoint is complete renal response at 6 months; listing posted on ClinicalTrials.gov.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aurinia Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260706998880) on July 06, 2026, and is solely responsible for the information contained therein.